Logo image of YMAB

Y-MABS THERAPEUTICS INC (YMAB) Stock Fundamental Analysis

NASDAQ:YMAB - Nasdaq - US9842411095 - Common Stock - Currency: USD

4.04  +0.16 (+4.12%)

After market: 3.98 -0.06 (-1.49%)

Fundamental Rating

3

Overall YMAB gets a fundamental rating of 3 out of 10. We evaluated YMAB against 563 industry peers in the Biotechnology industry. The financial health of YMAB is average, but there are quite some concerns on its profitability. YMAB is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

YMAB had negative earnings in the past year.
YMAB had a negative operating cash flow in the past year.
YMAB had negative earnings in each of the past 5 years.
YMAB had a negative operating cash flow in each of the past 5 years.
YMAB Yearly Net Income VS EBIT VS OCF VS FCFYMAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a decent Return On Assets value of -24.74%, YMAB is doing good in the industry, outperforming 72.11% of the companies in the same industry.
YMAB has a Return On Equity of -32.24%. This is in the better half of the industry: YMAB outperforms 75.84% of its industry peers.
Industry RankSector Rank
ROA -24.74%
ROE -32.24%
ROIC N/A
ROA(3y)-36.35%
ROA(5y)-45.09%
ROE(3y)-46.99%
ROE(5y)-56.89%
ROIC(3y)N/A
ROIC(5y)N/A
YMAB Yearly ROA, ROE, ROICYMAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

The Gross Margin of YMAB (82.89%) is better than 85.44% of its industry peers.
In the last couple of years the Gross Margin of YMAB has declined.
The Profit Margin and Operating Margin are not available for YMAB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 82.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.89%
GM growth 5YN/A
YMAB Yearly Profit, Operating, Gross MarginsYMAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

6

2. Health

2.1 Basic Checks

YMAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, YMAB has more shares outstanding
Compared to 5 years ago, YMAB has more shares outstanding
There is no outstanding debt for YMAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
YMAB Yearly Shares OutstandingYMAB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
YMAB Yearly Total Debt VS Total AssetsYMAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

YMAB has an Altman-Z score of -1.25. This is a bad value and indicates that YMAB is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of YMAB (-1.25) is comparable to the rest of the industry.
There is no outstanding debt for YMAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.25
ROIC/WACCN/A
WACC9.99%
YMAB Yearly LT Debt VS Equity VS FCFYMAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

A Current Ratio of 4.16 indicates that YMAB has no problem at all paying its short term obligations.
The Current ratio of YMAB (4.16) is comparable to the rest of the industry.
YMAB has a Quick Ratio of 3.85. This indicates that YMAB is financially healthy and has no problem in meeting its short term obligations.
YMAB has a Quick ratio (3.85) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.16
Quick Ratio 3.85
YMAB Yearly Current Assets VS Current LiabilitesYMAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for YMAB have decreased strongly by -36.73% in the last year.
The Revenue has been growing slightly by 3.39% in the past year.
YMAB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 35.95% yearly.
EPS 1Y (TTM)-36.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-650%
Revenue 1Y (TTM)3.39%
Revenue growth 3Y35.95%
Revenue growth 5YN/A
Sales Q2Q%13.41%

3.2 Future

YMAB is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -1.99% yearly.
The Revenue is expected to grow by 8.75% on average over the next years. This is quite good.
EPS Next Y-49.07%
EPS Next 2Y-21.75%
EPS Next 3Y-16.92%
EPS Next 5Y-1.99%
Revenue Next Year-6.77%
Revenue Next 2Y5.25%
Revenue Next 3Y8.12%
Revenue Next 5Y8.75%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
YMAB Yearly Revenue VS EstimatesYMAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
YMAB Yearly EPS VS EstimatesYMAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

YMAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year YMAB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
YMAB Price Earnings VS Forward Price EarningsYMAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
YMAB Per share dataYMAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

A cheap valuation may be justified as YMAB's earnings are expected to decrease with -16.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-21.75%
EPS Next 3Y-16.92%

More info and screens

0

5. Dividend

5.1 Amount

YMAB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Y-MABS THERAPEUTICS INC

NASDAQ:YMAB (5/8/2025, 5:38:06 PM)

After market: 3.98 -0.06 (-1.49%)

4.04

+0.16 (+4.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-04 2025-03-04/bmo
Earnings (Next)05-12 2025-05-12/amc
Inst Owners78.62%
Inst Owner Change-0.26%
Ins Owners1.96%
Ins Owner Change3.51%
Market Cap182.93M
Analysts80
Price Target16.13 (299.26%)
Short Float %7.77%
Short Ratio9.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-9.22%
Min EPS beat(2)-18.84%
Max EPS beat(2)0.4%
EPS beat(4)1
Avg EPS beat(4)-20.84%
Min EPS beat(4)-56.65%
Max EPS beat(4)0.4%
EPS beat(8)5
Avg EPS beat(8)13.68%
EPS beat(12)8
Avg EPS beat(12)16.91%
EPS beat(16)9
Avg EPS beat(16)-15.78%
Revenue beat(2)0
Avg Revenue beat(2)-13.51%
Min Revenue beat(2)-22.2%
Max Revenue beat(2)-4.81%
Revenue beat(4)0
Avg Revenue beat(4)-10.49%
Min Revenue beat(4)-22.2%
Max Revenue beat(4)-2.9%
Revenue beat(8)3
Avg Revenue beat(8)-0.79%
Revenue beat(12)5
Avg Revenue beat(12)3.2%
Revenue beat(16)6
Avg Revenue beat(16)-2.21%
PT rev (1m)-7.5%
PT rev (3m)-19.91%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-42.53%
EPS NY rev (1m)0%
EPS NY rev (3m)-67.2%
Revenue NQ rev (1m)-1.84%
Revenue NQ rev (3m)-19.57%
Revenue NY rev (1m)-1.25%
Revenue NY rev (3m)-21.83%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.09
P/FCF N/A
P/OCF N/A
P/B 1.99
P/tB 2.04
EV/EBITDA N/A
EPS(TTM)-0.67
EYN/A
EPS(NY)-1
Fwd EYN/A
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS1.94
BVpS2.03
TBVpS1.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.74%
ROE -32.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 82.89%
FCFM N/A
ROA(3y)-36.35%
ROA(5y)-45.09%
ROE(3y)-46.99%
ROE(5y)-56.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.89%
GM growth 5YN/A
F-Score3
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.16
Quick Ratio 3.85
Altman-Z -1.25
F-Score3
WACC9.99%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-36.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-650%
EPS Next Y-49.07%
EPS Next 2Y-21.75%
EPS Next 3Y-16.92%
EPS Next 5Y-1.99%
Revenue 1Y (TTM)3.39%
Revenue growth 3Y35.95%
Revenue growth 5YN/A
Sales Q2Q%13.41%
Revenue Next Year-6.77%
Revenue Next 2Y5.25%
Revenue Next 3Y8.12%
Revenue Next 5Y8.75%
EBIT growth 1Y-40.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-70.76%
EBIT Next 3Y-1.57%
EBIT Next 5YN/A
FCF growth 1Y42.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.3%
OCF growth 3YN/A
OCF growth 5YN/A